An observational study in Chronic Spontaneous Urticaria, sponsored by Novartis Pharmaceuticals. Recruiting at 1 site in United States. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-02-13.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Observational
How we know · 2 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies in Chronic Urticaria by Novartis — 7 open to participants now, 12 under way, 5 of them phase 3. Chronic Urticaria · Novartis.
Among the 38 studies in Chronic Urticaria by Novartis, this one is the 4th largest by planned enrollment of the 10 observational ones that give a count, is one of 7 that started in 2026, is one of 10 observational ones, reaches primary completion later than 9 of the 11 other live ones, and was the 32nd registered.
199 studies on the registry are indexed under Chronic Urticaria; 51 are open to participants now.
Browse Chronic Urticaria studies →7 of the 38 studies in Chronic Urticaria by Novartis are open now, in 9 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Canada, Hong Kong, Japan and 1 more country
Ages 18+
Novartis Pharmaceuticals · Sites in Germany
Ages 18+
Novartis Pharmaceuticals · Sites in United States
Ages 18+
Novartis Pharmaceuticals · Sites in United States
Ages 18–100
Novartis Pharmaceuticals · Sites in United States, France, Germany and 2 more countries
Ages 18+
By country, each count listing its studies:
Of the 25 Chronic Urticaria studies recruiting now, 11 (44%) set no upper age limit and 10 (40%) stop at 75 or younger; 1 takes children under 18; 6 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 7 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 505 is above the median of 163 across 41 observational studies indexed under Chronic Urticaria.
Median enrollment 270 across the 26 interventional studies, 484 across the 10 observational. Of the 24 that completed or were terminated, 19 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,723 studies on the registry; 222 are open to participants now.
Of its 587 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
3 of the studies in Chronic Urticaria by Novartis that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06868212Phase 3Novartis PharmaceuticalsA Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines | 2027-02-22 |
| NCT07408219Novartis PharmaceuticalsA Real-world Study of Remibrutinib in Chronic Spontaneous Urticaria Patients | 2026-12-31 |
| NCT06865651Novartis PharmaceuticalsStudy of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria | 2027-08-23 |
Add all 3 to your calendar (.ics) → With an account.
Among the 38 studies in Chronic Urticaria by Novartis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Prospective, non-interventional study in patients with CSU where the treatment decision prior enrolment has been made to either escalate current sgH1-AHs treatment or escalate/switch current treatment to remibrutinib. The primary aim of this study is to gather real-world effectiveness and safety data for remibrutinib, a new treatment option, covering a broader, real-world clinical practice population.
This is a prospective, non-interventional study in patients with CSU where the treatment decision prior enrolment has been made to either escalate current sgH1-AHs treatment or escalate/switch current treatment to remibrutinib. The primary aim of this study is to gather real-world effectiveness and safety data for remibrutinib, covering a broader, real-world clinical practice population. This local US study is part of an umbrella design which brings the evidence needs from multiple countries under the REASSERT global program (CLOU064A2402).
Patients with CSU where the treatment decision prior enrolment has been made to either escalate current sgH1-AHs treatment or escalate/switch current treatment to remibrutinib
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Cohort-specific observational inclusion criteria:
Note: Candidate patients must not have initiated the next escalated treatment step (i.e. up dosed AH for cohort 1, or remibrutinib for cohorts 2 and 3) prior to their enrolment to ensure the baseline visit captures their clinical status before treatment escalation.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Inadequate control of CSU despite licensed dose of sgH1-AH (no other pre-treatments permitted) and decision to escalate sgH1-AH treatment
Inadequate control of CSU despite licensed dose or escalated sgH1-AH(s) (no other pre-treatment with exception of first generation H1-AH permitted) with decision to switch to remibrutinib treatment as per local label
Any other treatment received in addition to H1-AH, any time during patients' CSU treatment history, with decision to switch to remibrutinib treatment as per local label
This study also gives RemibrutinibStudies of RemibrutinibRemibrutinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.
UAS7 score
Urticaria Activity Score over 7 days UAS7 is based on 2 daily questions scored 0-3 per day, ranging from 0 (complete control) to 42 (poor control)
Time frame: 12 weeks after initiating remibrutinib treatment
UCT7 score
Urticaria Control Test is looking retrospectively for 7 days (UCT7) and consists of 4 questions. Each question is scored 0-4, with a total score range of 0 (poor control) to 16 (well controlled).
Time frame: 12 weeks after initiating remibrutinib treatment
Number and proportion of participants with well-controlled disease and complete disease
Proportion of patients with UCT score ≥12 and UAS7 score ≤6. Urticaria Control Test (UCT) consists of 4 questions scored 0 (very much) to 4 (not at all), with a total score range of 0 to 16. High scores indicates better disease control. Urticaria Activity Score over 7 days (UAS7) is based on 2 daily questions, with daily score of 0 to 6 and weekly score of 0 to 42. Lower scores suggests urticaria free and well controlled urticaria.
Time frame: Up to 24 months
Change from baseline (CFB) in UCT score
Change in UCT score over time. Urticaria Control Test (UCT) consists of 4 questions scored 0 (very much) to 4 (not at all), with a total score range of 0 to 16. Highest scores indicates better disease control. The study is not powered to detect any specific difference and the purpose is to estimate any observed difference descriptively.
Time frame: Up to 24 months
Change from Baseline in UAS7 score ≥ minimal important difference
Urticaria Activity Score over 7 days (UAS7) is based on 2 daily questions, with daily score of 0 to 6 and weekly score of 0 to 42. Lower scores suggests urticaria free and well controlled urticaria. The study is not powered to detect any specific difference and the purpose is to estimate any observed difference descriptively.
Time frame: Up to 24 months
Change in angioedema activity score (AAS7) from baseline
Angioedema Activity Score (AAS7) is assessing disease activity over 7 days in patients with urticaria. The score is based on 5 daily questions scored 0 (no discomfort) to 3 (severe discomfort), with weekly score ranging from 0 to 15. Higher scores indicates greater severity of angioedema.
Time frame: Up to 24 months
Number of weeks without angioedema
Number of weeks without angioedema evaluated using application entries.
Time frame: Up to 24 months
Number of participants with rescue medication requirement
Number of participants with rescue medication requirement
Time frame: Up to 24 months
Characterize CSU relapse
CSU relapse by frequency and presentation
Time frame: Up to 24 months
UCT score
Urticaria Control Test (UCT) consists of 4 questions scored 0 (very much) to 4 (not at all), with a total score range of 0 to 16. High scores indicates better disease control. The study is not powered to detect any specific difference and the purpose is to estimate any observed difference descriptively.
Time frame: Up to 24 months
UAS7 score
Urticaria Activity Score over 7 days (UAS7) is based on 2 daily questions, with daily score of 0 to 6 and weekly score of 0 to 42. Lower scores suggests urticaria free and well controlled urticaria. The study is not powered to detect any specific difference, descriptive analysis of difference over time will be presented.
Time frame: Up to 24 months
Number of participants with administration of remibrutinib as monotherapy
Number of participants with remibrutinib as monotherapy in cohort 2 and 3
Time frame: Up to 24 months
Monotherapy duration
Duration of remibrutinib as monotherapy expressed by days, weeks or months in cohort 2 and 3
Time frame: Up to 24 months
Number of participants with Administration of remibrutinib as monotherapy with "on demand" sgH1-AH
Number of participants with Administration of remibrutinib as monotherapy with "on demand" sgH1-AH in cohort 2 and 3
Time frame: Up to 24 months
Duration of monotherapy with "on demand" sgH1-AH
Duration of remibrutinib therapy with "on demand" sgH1-AH expressed by days, weeks or months in cohort 2 and 3
Time frame: Up to 24 months
Number of participants with usage of concomitant sgH1-AHs and additional prescribed CSU treatments
Descriptive analysis of concomitant sgH1-AHs
Time frame: Up to 24 months
Number of participants with administration of CSU-related treatment(s) outside of local and/or international guidelines
Number of participants with administration of CSU-related treatment(s) outside of local and/or international guidelines
Time frame: Up to 24 months
Demonstrate relationship between non-adherence to local/international guidelines and impact on patient, disease control, treatment patterns and HCRU during early and long-term follow-up
Demonstrate relationship between non-adherence to local/international guidelines and impact on patient, disease control, treatment patterns and HCRU during early and long-term follow-up
Time frame: Up to 24 months
Delay of treatment escalation contrary to local and/or international guidelines when UCT <12 or UAS>6
Delay of treatment escalation contrary within 2-4 weeks from up-dosed sgH1-AH when UCT \<12 or UAS\>6 at time points measuring UCT7 (early) / UCT (month 3 onwards) / UAS7 group. This will be measured by time in days/months without escalation, with UCT\<12 or UAS7\>6 at time points measuring UCT7 / UCT (month 3 onwards) / UAS7 group
Time frame: Up to 24 months
Time without escalation, with UCT<12 or UAS7>6
Time in days/months without escalation while UCT score is below 12 OR UAS7 score above 6. Urticaria Control Test consists of 4 questions, score below 12 indicates poor disease control. Urticaria Activity Score over 7 days is based on 2 daily questions with a maximum daily score of 6 and weekly total score up to 42. Lower scores indicates better urticaria control.
Time frame: Up to 24 months
Number of participants with escalation to remibrutinib
Number of patients with escalation to remibrutinib (cohort 1), time to escalate, prior medications/escalations, and disease control at time of escalation will be presented.
Time frame: Up to 24 months
Number of participants with administration of above the licensed dose of sgH1-AH prior to remibrutinib switch
Number of participants receiving escalated doses of sgH1-AH above the licensed dose (2 times, 3 times, 4 times, \>4 times) prior to remibrutinib switch. This will be presented for cohort 1 and 2.
Time frame: Up to 24 months
Number of sgH1-AH treatment escalations and switches prior to remibrutinib escalation
Number of sgH1-AH treatment escalations and switches prior to remibrutinib escalation
Time frame: Up to 24 months
Demonstrate benefit of early vs late treatment escalation to remibrutinib
Demonstrate benefit of early vs late treatment escalation to remibrutinib
Time frame: Up to 24 months
Proportion of patients with uncontrolled angioedema escalated to remibrutinib
Presence of angioedema will be reported through App and/or derived from AAS scores
Time frame: Up to 24 months
Proportion of patients requiring corticosteroids prior to switch to remibrutinib
Proportion of patients requiring corticosteroids for disease control prior to switch to remibrutinib (cohort 1 and 2)
Time frame: Up to 24 months
Quality of life measured through DLQI score
Dermatology Life Quality Index (DLQI) score consists of 10 questions scored from 0 (no impact at all) to 3 (very much). Total score ranges from 0 to 30, with lower scores showing lowest impact of disease on quality of life.
Time frame: Up to 24 months
Quality of life evaluated through Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) questionnaire scores
Change over time in Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) questionnaire. CU-Q2oL consists of 20 items rated from 0 (never) to 5 (very often). Total score ranges from 0 to 25, with lower scores showing better urticaria control. The study is not powered to detect any specific difference, descriptive analysis of difference over time will be presented.
Time frame: Up to 24 months
Quality of life measured through Sleep interference score
Sleep interference will be evaluated though bespoke question. Maximum score along 7 days ranges from 0 to 21, lower scores showing lowest interference of CSU with sleep.
Time frame: Up to week 12
Quality of life measured through Hospital anxiety and depression scale (HADS)
Quality of life will be evaluated through HADS measuring anxiety and depression components, as well as change from baseline in HADS score. Hospital Anxiety and Depression Score (HADS) is a 14 item questionnaire, 7 item rating anxiety and 7 depression. Responses are rated from 0 (never) to 3 (almost all time) at each question. Total score for anxiety and total score for depression range from 0 to 21, higher scores showing higher anxious/depressive symptomatology. Descriptive analysis will be presented.
Time frame: Up to 24 months
Number of events related to CSU or Health Care Resource utilisation
Health Care resource utilisation (HCRU) will be evaluated based on quarterly and annualized number of health care resource utilisation related to CSU.
Time frame: Up to 24 months
Work productivity and activity impairment (WPAI-CU) score
Work productivity assessed through WPAI questionnaire which consists of 6 questions, used to calculate 4 types of scores, absenteeism (work time missed), presenteeism (impairment at work/reduced on the job effectiveness), work productivity loss (overall work impairment), and activity impairment. The scores are expressed in percentage with higher numbers indicating greater impairment and less productivity at work.
Time frame: Up to 24 months
Incidence of AEs
Incidence of AEs, including serious AEs in patients who initiated remibrutinib and in patients with sgH1-AH treatment alone
Time frame: Up to 24 months
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2026 (actual). Primary completion is estimated for Sep 2029, 43 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.